As part of its highly successful ongoing marketing push, Rainbow Coral Corp.’s (OTCBB: RBCC) technology partner Nano3D Biosciences (n3D) will demonstrate its incredible new 3-D cell culturing system later this month at a landmark conference gathering top thought leaders in cell culture models from around the country.
Nano3D Biosciences officers are scheduled to make three presentations at the Functional Analysis and Screening Technologies (FAST) Congress in Cambridge, Mass., on October 28-29. The presentations will be part of the Cambridge Healthtech Institute's Second Annual Engineering Functional 3-D Tissue Models meeting, a professional gathering of engineers, biologists and pharmacologists that will explore the latest insights into drug discovery and development, from designing the bioreactors to engineering the 3-D models and utilizing drug screening assays.
“This will be a unique opportunity for our partners to offer up practical discussion, solutions and case studies for refining first-stage drug discovery methods using the Bio-Assembler,” said RBCC CEO Patrick Brown. “It will be a true privilege to have our device highlighted at this high-profile conference gathering all of the top experts in 3D tissue engineering.”
Rainbow BioSciences, RBCC’s biotech subsidiary, acquired an equity interest in n3D last year, positioning the company to participate in the potentially impressive upside in store for n3D. Rainbow Biosciences is dedicated to the marketing and development of new medical and research technology innovations designed to help capture a growing share of a booming biotech industry alongside Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN).
For more information on RBCC’s partnership with n3D and other biotech initiatives, please visit www.rainbowbiosciences.com/investors.html.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Patrick Brown, 850-269-7230
President and CEO
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here